Suggested remit: To appraise the clinical and cost effectiveness of elexacaftor in combination with tezacaftor and ivacaftor within its marketing authorisation for treating cystic fibrosis in people with at least one F508del mutation.
Status Proposed
Process STA 2018
ID number 1661

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
03 February 2020 (10:00) Scoping workshop (Manchester)
12 December 2019 - 17 January 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance